AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24154560 — intervention group
Group type: COMPARATOR
Intervention: resistance training (n = 10)
Number of subjects: 21
Study 22814048 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial PRK
Number of subjects: 66
Study 22814048 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-assisted PRK
Number of subjects: 66
Study 20151251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Na-HA)
Number of subjects: 51
Study 20151251 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (CS)
Number of subjects: 51
Study 17684044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone levels measured at baseline and again at 3 and 6 months (total, free, and bioavailable testosterone, dihydrotestosterone, SHBG, LH, dehydroepiandrosterone, dehydroepiandrosterone sulfate, estrone, estradiol, cortisol)
Number of subjects: 121
Study 15589567 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion (150 mg, PO)
Number of subjects: 20
Study 15589567 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 15589567 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion (open-label treatment for 8 weeks)
Number of subjects: 20
Study 12182278 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group, 6-session communally oriented HIV prevention intervention
Number of subjects: 935
Study 12182278 — intervention group
Group type: COMPARATOR
Intervention: Yoked general health promotion intervention control
Number of subjects: 935
Study 12182278 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 935
Study 12182278 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention group
Number of subjects: 935
Study 10219064 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping primary prophylaxis against Pneumocystis carinii pneumonia
Number of subjects: 262
Study 7777105 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 24
Study 7777105 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cycle peritoneal dialysis (CCPD)
Number of subjects: 24
Study 2321780 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 45
Study 2321780 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 45
Study 119198 — intervention group
Group type: EXPERIMENTAL
Intervention: idoxuridine
Number of subjects: 0
Study 119198 — intervention group
Group type: EXPERIMENTAL
Intervention: vidarabine (Ara‐A)
Number of subjects: 0
Study 119198 — intervention group
Group type: EXPERIMENTAL
Intervention: trifluorothymidine
Number of subjects: 0
Study 119198 — intervention group
Group type: EXPERIMENTAL
Intervention: acycloguanosine
Number of subjects: 0
Study 31264007 — intervention group
Group type: EXPERIMENTAL
Intervention: ELCA plus DCB
Number of subjects: 40
Study 31264007 — intervention group
Group type: COMPARATOR
Intervention: DCB alone
Number of subjects: 40
Study 31203208 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliSpace Portal (ISP)
Number of subjects: 35
Study 31203208 — intervention group
Group type: EXPERIMENTAL
Intervention: syngo.via method A
Number of subjects: 35
Study 31203208 — intervention group
Group type: EXPERIMENTAL
Intervention: syngo.via method B (additional smoothing)
Number of subjects: 35
Study 31203208 — intervention group
Group type: EXPERIMENTAL
Intervention: syngo.via method C (adjusted settings)
Number of subjects: 35
Study 31203208 — intervention group
Group type: COMPARATOR
Intervention: RAPID
Number of subjects: 35
Study 28564569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, Velpatasvir, and Voxilaprevir (150 patients in POLARIS-1)
Number of subjects: 482
Study 28564569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, Velpatasvir, and Voxilaprevir (163 patients in POLARIS-4)
Number of subjects: 482
Study 28564569 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir and Velpatasvir (151 patients in POLARIS-4)
Number of subjects: 482
Study 28564569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 patients in POLARIS-1)
Number of subjects: 482
Study 25559818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trastuzumab and lapatinib
Number of subjects: 0
Study 23692553 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily extended-release topiramate (USL255)
Number of subjects: 0
Study 21337293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical consulting intervention by pharmacists regarding optimized antibiotic therapy
Number of subjects: 638
Study 21337293 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 638
Study 21337293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical consulting intervention
Number of subjects: 638
Study 20034313 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist posture with flexion/extension and ulnar deviation
Number of subjects: 0
Study 17204956 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg 13C‐urea
Number of subjects: 40
Study 17204956 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg 13C‐urea
Number of subjects: 40
Study 17204956 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐urea blood test (both dosages)
Number of subjects: 40
Study 15063432 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg
Number of subjects: 3381
Study 15063432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3381
Study 11204897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg for males and 0.5 g/kg for females)
Number of subjects: 38
Study 11204897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9744369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 994
Study 9744369 — intervention group
Group type: COMPARATOR
Intervention: Enucleation alone
Number of subjects: 994
Study 9083731 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide/oxygen mixture
Number of subjects: 37
Study 9083731 — intervention group
Group type: COMPARATOR
Intervention: Conventional sedation (pethidine 25-50 mg and midazolam 2.5 mg)
Number of subjects: 37
Study 2022828 — intervention group
Group type: COMPARATOR
Intervention: Decompression of the transverse carpal ligament
Number of subjects: 59
Study 2022828 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression of the transverse carpal ligament with internal neurolysis of the median nerve
Number of subjects: 59
Study 7148367 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 30
Study 7148367 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 30
Study 28825227 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for breast cancer
Number of subjects: 321
Study 25706240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 1766
Study 25706240 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1766
Study 25706240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1766
Study 24717951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 12 months
Number of subjects: 264
Study 24717951 — intervention group
Group type: COMPARATOR
Intervention: No SLIT (control group)
Number of subjects: 264
Study 22614882 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 95
Study 22614882 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 95
Study 19389245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 237
Study 19389245 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal Psychodynamic Therapy (FPT)
Number of subjects: 237
Study 19389245 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 237
Study 17613112 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acupuncture
Number of subjects: 0
Study 17613112 — intervention group
Group type: EXPERIMENTAL
Intervention: VaD-specific needling (additional to conventional acupuncture)
Number of subjects: 0
Study 15223738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise programme
Number of subjects: 16
Study 15223738 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 12170445 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) plus cisplatin 75 mg/m(2) every 3 weeks
Number of subjects: 1220
Study 12170445 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) plus carboplatin to an AUC of 6 every 3 weeks
Number of subjects: 1220
Study 12170445 — intervention group
Group type: COMPARATOR
Intervention: vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 plus cisplatin 100 mg/m(2) on day 1 every 4 weeks
Number of subjects: 1220
Study 9174680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous valsartan (5, 10, and 20 mg)
Number of subjects: 0
Study 9174680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valsartan (80 mg capsule)
Number of subjects: 0
Study 9174680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valsartan (buffered solution, 80 mg)
Number of subjects: 0
Study 9174680 — intervention group
Group type: COMPARATOR
Intervention: Intravenous valsartan (20 mg)
Number of subjects: 0
Study 1606859 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction-free drainages
Number of subjects: 40
Study 1606859 — intervention group
Group type: EXPERIMENTAL
Intervention: Drains with a long period of suction
Number of subjects: 40
Study 1606859 — intervention group
Group type: COMPARATOR
Intervention: High vacuum drains
Number of subjects: 40
Study 1606859 — intervention group
Group type: COMPARATOR
Intervention: All groups (including high vacuum, middle vacuum, low vacuum, suction-free)
Number of subjects: 40
Study 1606859 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction-free and reduced vacuum drains
Number of subjects: 40
Study 2859199 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 150 mg
Number of subjects: 6
Study 2859199 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg
Number of subjects: 6
Study 2859199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30395532 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% volume exposure for 30 minutes through iPod Touch
Number of subjects: 40
Study 30395532 — intervention group
Group type: COMPARATOR
Intervention: 75% volume exposure for 30 minutes through iPod Touch
Number of subjects: 40
Study 30395532 — intervention group
Group type: COMPARATOR
Intervention: 50% volume exposure for 30 minutes through iPod Touch
Number of subjects: 40
Study 30395532 — intervention group
Group type: COMPARATOR
Intervention: 0% volume exposure (no music) for 30 minutes through iPod Touch
Number of subjects: 40
Study 29055966 — intervention group
Group type: EXPERIMENTAL
Intervention: PNIF
Number of subjects: 20
Study 29055966 — intervention group
Group type: EXPERIMENTAL
Intervention: unilateral PNIF
Number of subjects: 20
Study 29055966 — intervention group
Group type: EXPERIMENTAL
Intervention: AAR
Number of subjects: 20
Study 29055966 — intervention group
Group type: EXPERIMENTAL
Intervention: PNIF and AAR
Number of subjects: 20
Study 26555953 — intervention group
Group type: EXPERIMENTAL
Intervention: External physical vibration lithecbole after shock wave lithotripsy
Number of subjects: 71
Study 26555953 — intervention group
Group type: COMPARATOR
Intervention: Shock wave lithotripsy only
Number of subjects: 71
Study 25062395 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS‐BLED score and estimated annual risk of bleeding
Number of subjects: 203
Study 25062395 — intervention group
Group type: COMPARATOR
Intervention: No HAS‐BLED score
Number of subjects: 203
Study 23019938 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule (CXC) and Clomiphene Citrate (CC)
Number of subjects: 87
Study 23019938 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) alone
Number of subjects: 87
Study 20081549 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Refraction (SR)
Number of subjects: 100
Study 20081549 — intervention group
Group type: EXPERIMENTAL
Intervention: AdSpecs
Number of subjects: 100
Study 20081549 — intervention group
Group type: EXPERIMENTAL
Intervention: Focometer
Number of subjects: 100
Study 20081549 — intervention group
Group type: EXPERIMENTAL
Intervention: Predetermined Lens Refraction (PLR)
Number of subjects: 100
Study 17901792 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 2523
Study 17901792 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoroquinolone antibiotics
Number of subjects: 2523
Study 16213381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (five weekly intra-articular injections)
Number of subjects: 0
Study 16213381 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (control)
Number of subjects: 0
Study 11825860 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg GHB/kg body wt
Number of subjects: 98
Study 11825860 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg GHB/kg body wt
Number of subjects: 98
Study 11825860 — intervention group
Group type: COMPARATOR
Intervention: clomethiazole 1000 mg daily (CLO group)
Number of subjects: 98
Study 11825860 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (both dosages)
Number of subjects: 98
Study 10553535 — intervention group
Group type: EXPERIMENTAL
Intervention: Gangliosides treatment (100 mg/day for 15 days followed by 40 mg/day for 75 days)
Number of subjects: 90
Study 10553535 — intervention group
Group type: EXPERIMENTAL
Intervention: Gangliosides treatment (continuous treatment for 12 months)
Number of subjects: 90
Study 10553535 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 10553535 — intervention group
Group type: EXPERIMENTAL
Intervention: Gangliosides treatment
Number of subjects: 90
Study 7793220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 7793220 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study 1869064 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (30 mg/kg)
Number of subjects: 9
Study 1869064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6132179 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan 6 mg/m2 daily for 5 days every 6 weeks for sixteen cycles
Number of subjects: 370
Study 6132179 — intervention group
Group type: COMPARATOR
Intervention: no additional treatment
Number of subjects: 370
Study 31027423 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligners
Number of subjects: 40
Study 31027423 — intervention group
Group type: COMPARATOR
Intervention: Labial fixed appliances
Number of subjects: 40
Study 31027423 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 30684327 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 whole-body cryotherapy treatments associated with 30-minute kinesitherapy
Number of subjects: 48
Study 30684327 — intervention group
Group type: COMPARATOR
Intervention: Kinesitherapy only (control group)
Number of subjects: 48
Study 26582640 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking in water
Number of subjects: 10
Study 26582640 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking on land
Number of subjects: 10
Study 24781074 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 830
Study 24781074 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 830
Study 22331457 — intervention group
Group type: EXPERIMENTAL
Intervention: Grewia oppositifolia leaves
Number of subjects: 36
Study 22331457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cottonseed cake (CSC)
Number of subjects: 36
Study 22331457 — intervention group
Group type: COMPARATOR
Intervention: Control group (local pasture only)
Number of subjects: 36
Study 20702659 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg twice daily)
Number of subjects: 64
Study 20702659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 17383494 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 121
Study 17383494 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo (control)
Number of subjects: 121
Study 15802370 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 19
Study 15802370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 19
Study 15802370 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (alpha(1)-agonist)
Number of subjects: 19
Study 12375540 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 128
Study 12375540 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen cream
Number of subjects: 128
Study 12375540 — intervention group
Group type: COMPARATOR
Intervention: Inert lubricant jelly (Control)
Number of subjects: 128
Study 9640069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelentan (Hypoprothrombinemia Provocation Test) administered to patients with suspected hepatic injury and alcohol abusers
Number of subjects: 172
Study 9640069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelentan (Hypoprothrombinemia Provocation Test) administered
Number of subjects: 172
Study 9640069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelentan (Hypoprothrombinemia Provocation Test)
Number of subjects: 172
Study 9640069 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically healthy people not exposed to toxic agents)
Number of subjects: 172
Study 7521534 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/day
Number of subjects: 88
Study 7521534 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg/day
Number of subjects: 88
Study 7521534 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg/day
Number of subjects: 88
Study 7521534 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 88
Study 2729124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 12
Study 2729124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31493725 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS applied during MT (concurrent‐tDCS group)
Number of subjects: 30
Study 31493725 — intervention group
Group type: COMPARATOR
Intervention: tDCS applied before MT (prior‐tDCS group)
Number of subjects: 30
Study 31493725 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (sham‐tDCS group)
Number of subjects: 30
Study 28254097 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Acp)
Number of subjects: 7
Study 28254097 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and Moxibustion (Acp-Mox)
Number of subjects: 7
Study 28254097 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study 26025699 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminders for clinical appointments
Number of subjects: 200
Study 26025699 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetes care
Number of subjects: 200
Study 22748085 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual chest physiotherapy (MCP) plus advice on airway clearance
Number of subjects: 526
Study 22748085 — intervention group
Group type: COMPARATOR
Intervention: Advice on chest clearance alone
Number of subjects: 526
Study 20038724 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide, epirubicin, and fluorouracil)
Number of subjects: 980
Study 20038724 — intervention group
Group type: EXPERIMENTAL
Intervention: 2T (TOP2A with TIMP‐1)
Number of subjects: 980
Study 20038724 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 980
Study 18387567 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger-differentiation training programme (G1) - 2 weekly sessions of half an hour each for 8 weeks
Number of subjects: 47
Study 18387567 — intervention group
Group type: COMPARATOR
Intervention: Control-intervention (story comprehension training, G2)
Number of subjects: 47
Study 18387567 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal school lessons (G3)
Number of subjects: 47
Study 15770171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions including the Dutch low back pain guideline, a 2-hour educational workshop, scientific articles, and tools for patient education and agreement on low back care
Number of subjects: 531
Study 15770171 — intervention group
Group type: COMPARATOR
Intervention: Control group received no intervention
Number of subjects: 531
Study 12176950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 238
Study 12176950 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stent
Number of subjects: 238
Study 10027429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 261
Study 10027429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 10027429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily) with PEF variability >= 20%
Number of subjects: 261
Study 10027429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily) with PEF variability < 20%
Number of subjects: 261
Study 7570569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell washing (CS)
Number of subjects: 20
Study 7570569 — intervention group
Group type: COMPARATOR
Intervention: Whole blood filtration (WB)
Number of subjects: 20
Study 2405348 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole for 4 weeks
Number of subjects: 76
Study 2405348 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisone for 2 weeks
Number of subjects: 76
Study 2405348 — intervention group
Group type: COMPARATOR
Intervention: aluminum ibuprofen suspension for 2 weeks
Number of subjects: 76
Study 2405348 — intervention group
Group type: COMPARATOR
Intervention: control (no treatment)
Number of subjects: 76
Study 2405348 — intervention group
Group type: EXPERIMENTAL
Intervention: all groups after 12 months follow-up
Number of subjects: 76
Study 7008643 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg I.V.
Number of subjects: 100